Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 3, 2016, Pages 624-628

  Orio, Peter F ^a,b   Nguyen, Paul L ^a,b   Buzurovic, Ivan ^a,b   Cail, Daniel W ^a   Chen, Yu Wei ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; EDUCATION; ONCOLOGY; UROLOGY;

BRACHYTHERAPY; CASE VOLUME; IMPLICATIONS FOR FUTURES; METHODS AND MATERIALS; NATIONAL PRACTICES; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; RADIATION ONCOLOGY;

RADIOTHERAPY;

ACADEMIC PRACTICE; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONACADEMIC PRACTICE; PRIORITY JOURNAL; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; RESIDENCY EDUCATION; RESIDENT; MEDICAL EDUCATION; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; UNIVERSITY HOSPITAL; UTILIZATION; UTILIZATION REVIEW;

ACADEMIC MEDICAL CENTERS; BRACHYTHERAPY; HUMANS; INTERNSHIP AND RESIDENCY; MALE; PRACTICE PATTERNS, PHYSICIANS'; PROSTATIC NEOPLASMS; UNITED STATES; UTILIZATION REVIEW;

EID: 84990852946     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.07.013     Document Type: Article

References (18)

1. 1 Orio, P.F. III, Nguyen, P.L., Buzurovic, I., et al. The decreased use of brachytherapy boost for intermediate and high risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy, 2016, 10.1016/j.brachy.2016.05.001 [e-pub ahead of print]. Accessed June 1, 2016.
2. 2 Martin, J.M., Handorf, E.A., Kutikov, A., et al. The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer 120 (2014), 2114–2121.
3. 3 Mahmood, U., Pugh, T., Frank, S., et al. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy 13 (2014), 157–162.
4. 4 Grimm, P., Billiet, I., Bostwick, D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:Suppl 1 (2012), 22–29.
5. 5 Morris, W.J., Tyldesley, S., Pai, H.H., et al. ASCENDE-RT*: A multipractice, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol, 33(Suppl 7), 2015 Abstract 3.
6. 6 Hoskin, P.J., Rojas, A.M., Bownes, P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103 (2012), 217–222.
7. 7 Bilimoria, K.Y., Stewart, A.K., Winchester, D.P., et al. The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15 (2008), 683–690.
8. 8 Mohanty, S., Bilimoria, K.Y., Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. J Surg Oncol 109 (2014), 629–630.
9. 9 United States Government Accountability Office. MEDICARE: Higher Use of Costly Prostate Cancer Treatment by Providers Who Self-Refer Warrants Scrutiny. Available at: http://www.gao.gov/products/GAO-13-525, 2013 Accessed May 15, 2016.
10. 10 Wilson, L.S., Tesoro, R., Elkin, E.P., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007), 518–527.
11. 11 Vigneri, P., Herati, A.S., Potters, L., The second decade of prostate brachytherapy: Evidence and cost based outcomes. Urol Oncol 28 (2010), 86–90.
12. 12 Durkee, B.Y., Buyyounouski, M.K., The case for prostate brachytherapy in the Affordable Care Act era. Int J Radiat Oncol Biol Phys 91 (2015), 465–467.
13. 13 Miller, P., Mosley, K., Physician reimbursement: From fee-for-service to MACRA, MIPS and APMs. J Med Pract Manage 31 (2016), 266–269.
14. 14 Hayes, J.H., Barry, M.J., McMahon, P.M., Observation versus initial treatment for prostate cancer. Ann Intern Med, 159, 2013, 574.
15. 15 Compton, J.J., Gaspar, L.E., Shrieve, D.C., et al. Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs. Brachytherapy 12 (2013), 622–627.
16. 16 Gondi, V., Bernard, J.R. Jr., Jabbari, S., et al. Results of the 2005-2008 Association of Residents in Radiation Oncology survey of chief residents in the United States: Clinical training and resident working conditions. Int J Radiat Oncol Biol Phys 81 (2011), 1120–1127.
17. 17 Nabavizadeh, N., Burt, L.M., Mancini, B.R., et al. Results of the 2013-2015 Association of Residents in Radiation Oncology survey of chief residents in the United States. Int J Radiat Oncol Biol Phys 94 (2016), 228–234.
18. 18 Ollendorf, D.A., Hayes, J., McMahon, P., et al. Management options for low-risk prostate cancer: A report on comparative effectiveness and value. 2010, Institute for Clinical and Economic Review, Boston.